SCHEMBL1245099

SCHEMBL1245099

CC1(OC(=O)Cl)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3295397 0.90
SCHEMBL10702855 0.90 CYP19A1 (0.40)
SCHEMBL318859 0.87 CYP19A1 (0.42)
SCHEMBL3296993 0.82 SCN1A (0.57)
SCHEMBL21933087 0.79 SCN1A (0.34)
SCHEMBL10696503 0.77
SCHEMBL11372188 0.77 SCN1A (0.32)
SCHEMBL12988127 0.77 FFAR3 (0.36)
SCHEMBL1287801 0.74
SCHEMBL3670104 0.74

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119414507-A Resin composition, compound, substrate, optical filter, solid-state imaging device, and optical sensor device JSR株式会社 2025-02-11 CN disclosed
CN-113292807-B Resin composition, compound, substrate, optical filter, solid-state imaging device, and optical sensor device JSR株式会社 2024-11-22 CN disclosed
CN-117757205-A Resin composition, compound, substrate, optical filter, solid-state imaging device, and optical sensor device JSR株式会社 2024-03-26 CN disclosed
WO-2023083373-A1 COMPOUND USED AS SRC INHIBITOR 微境生物医药科技(上海)有限公司 2023-05-19 WO disclosed
US-8202868-B2 4-piperazinyl-pyrimidine compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor ABBOTT GMBH & CO. KG (DE) 2012-06-19 US disclosed
WO-2011014520-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-02-03 WO disclosed
EP-2177523-A1 Novel macrocyclic inhibitors of hepatitis c virus replication Intermune, Inc. (US) 2010-04-21 EP disclosed
EP-2177523-A1 Novel macrocyclic inhibitors of hepatitis c virus replication Intermune, Inc. (US) 2010-04-21 EP disclosed
EP-2160392-A2 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION Intermune, Inc. (US) 2010-03-10 EP disclosed
EP-1778684-B1 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D&lt;sb&gt;3&lt;/sb&gt; RECEPTOR ABBOTT GMBH & CO KG (DE) 2009-12-16 EP disclosed
US-20090155209-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. 2009-06-18 US disclosed
US-20090155209-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. 2009-06-18 US disclosed
US-20090155209-A1 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. 2009-06-18 US disclosed
WO-2008137779-A2 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-11-13 WO disclosed
WO-2008137779-A2 NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-11-13 WO disclosed
EP-1778684-A1 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D&amp;lt;sb&amp;gt;3&amp;lt;/sb&amp;gt; RECEPTOR Abbott GmbH & Co. KG (DE) 2007-05-02 EP disclosed
WO-2006015842-A1 4-PIPERAZINYL-PYRIMIDINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-02-16 WO disclosed
US-4665093-A FUNGICIDES CHEVRON RESEARCH COMPANY (US) 1987-05-12 US disclosed
US-4339591-A Process for the production of caboxylic acid cyanides DEGUSSA AKTIENGESELLSCHAFT (DE) 1982-07-13 US disclosed
US-4122116-A HERBICIDES DEUTSCHE GOLD- UND SILBER- SCHEIDEANSTALT VORMALS ROESSLER (DE) 1978-10-24 US disclosed